Accentia Biopharmaceuticals Inc : Article Published on Fox News Website Predicts the Advance of Cancer Vaccines in 2012 including BiovaxID® Lymphoma Vaccine

Biovest International, Inc. (OTCQB: "BVTI"), a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. (OTCQB: "ABPI"), today announced that an article published by 'MyHealthNewsDaily' was featured on the Fox News website, forecasting the top five medical breakthroughs in 2012 with the top prediction covering the advancement of cancer vaccines including Biovest's BiovaxID® personalized cancer vaccine for the treatment of non-Hodgkin's lymphoma.

In discussing this prediction, the article notes that the U.S. Food and Drug Administration approved the first cancer vaccine, Provenge®, in the spring of 2010 for the treatment of prostate cancer and that a vaccine for melanoma performed well in the final stages of clinical trials last year. The article also covers BiovaxID®, which is referred to in the article as "Kwak's vaccine", reporting that it has passed its Phase III trials and is moving toward the final steps of regulatory approval.

The article, titled, "5 Medical Advances Predicted for 2012" includes an interview with Biovest's clinical consultant, Dr. Larry Kwak, M.D., Ph.D., who is the Chairman of the Department of Lymphoma/Myeloma at the M. D. Anderson Cancer Center. Dr. Kwak was named to TIME Magazine's "Top 100 - Most Influential People in the World" list in 2010 for his work on BiovaxID. In the article, Dr. Kwak stated, "What ties them (cancer vaccines) together is they are activating the immune system so it's primed and ready to fight".

According to Samuel S. Duffey, Biovest's President & CEO, "I fully agree with this article's prediction, as decades of clinical trials evaluating many kinds of cancer vaccines with both successes and failures have provided invaluable data, allowing us to far better understand the important role that the patient's own immune system can play in the fight against cancer. With our product, BiovaxID, we have observed profound benefit by vaccinating lymphoma patients in remission against relapse and significantly extending many patients' ability to stay cancer-free by stimulating potent and durable immune response. In my opinion, we are indeed coming into an exciting time when medicine is getting closer to treating cancer with vaccines that can very safely train the patient's immune system to attack existing or newly arising tumor cells."

The Fox News article can be accessed in the Media Center at Biovest's corporate website at: .

About BiovaxID®

Biovest's lead drug product is BiovaxID®, an autologous active immunotherapy (personalized cancer vaccine) for the treatment of certain B-cell subtypes of non-Hodgkin's lymphoma, an incurable form of blood cancer. Over the past decade, two Phase II clinical trials and a Phase III clinical trial have demonstrated strong and cumulative evidence with regards to BiovaxID vaccination's safety and efficacy. With regards to safety, all clinical trials to date demonstrate that BiovaxID vaccination is highly safe and poses a nearly vanishingly small toxicity risk relative to approved anti-lymphoma agents. Moreover, BiovaxID provides substantial and durable clinical efficacy with the Phase III clinical trial demonstrating that BiovaxID significantly improves disease-free survival in follicular lymphoma and the Phase II mantle cell lymphoma clinical trial demonstrating that BiovaxID induces strong idiotype-specific T-cell responses which strongly correlate with highly-statistically significant overall survival.

About Biovest International, Inc.

Biovest International, Inc. is an emerging leader in the field of active personalized immunotherapies. In collaboration with the National Cancer Institute, Biovest has developed a patient-specific, cancer vaccine, BiovaxID®, with three clinical trials completed, including a Phase III study, demonstrating evidence of safety and efficacy for the treatment of indolent follicular non-Hodgkin's lymphoma.

Headquartered in Tampa, Florida with its bio-manufacturing facility based in Minneapolis, Minnesota, Biovest is publicly-traded on the OTCQB™ Market with the stock-ticker symbol "BVTI", and is a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. (OTCQB: "ABPI").

Forward-Looking Statements:

Statements in this release that are not strictly historical in nature constitute "forward-looking statements."Such statements include, but are not limited to statements about BiovaxID®, AutovaxID®, events occurring after dates hereof, and any other statements relating to products, product candidates, product development programs, the FDA or clinical study process including the commencement, process, or completion of clinical trials or the regulatory process.Such statements may include, without limitation, statements with respect to the Company's plans, objectives, expectations and intentions, and other statements identified by words such as "may," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," or similar expressions.Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause the actual results of Biovest to be materially different from historical results or from any results expressed or implied by such forward-looking statements.These factors include, but are not limited to, risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval for product candidates; competition from other pharmaceutical or biotechnology companies; and the additional risks discussed in filings with the Securities and Exchange Commission.All forward-looking statements are qualified in their entirety by this cautionary statement, and Biovest undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. The product names used in this statement are for identification purposes only. All trademarks and registered trademarks are the property of their respective owners.